Cargando…

Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice

OBJECTIVE: Calcitonin gene–related peptide (CGRP) pathway inhibitors are emerging treatments for migraine. CGRP‐mediated vasodilation is, however, a critical rescue mechanism in ischemia. We, therefore, investigated whether gepants, small molecule CGRP receptor antagonists, worsen cerebral ischemia....

Descripción completa

Detalles Bibliográficos
Autores principales: Mulder, Inge A., Li, Mei, de Vries, Tessa, Qin, Tao, Yanagisawa, Takeshi, Sugimoto, Kazutaka, van den Bogaerdt, Antoon, Danser, A. H. Jan, Wermer, Marieke J. H., van den Maagdenberg, Arn M. J. M., MaassenVanDenBrink, Antoinette, Ferrari, Michel D., Ayata, Cenk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540520/
https://www.ncbi.nlm.nih.gov/pubmed/32583883
http://dx.doi.org/10.1002/ana.25831
_version_ 1783591227680096256
author Mulder, Inge A.
Li, Mei
de Vries, Tessa
Qin, Tao
Yanagisawa, Takeshi
Sugimoto, Kazutaka
van den Bogaerdt, Antoon
Danser, A. H. Jan
Wermer, Marieke J. H.
van den Maagdenberg, Arn M. J. M.
MaassenVanDenBrink, Antoinette
Ferrari, Michel D.
Ayata, Cenk
author_facet Mulder, Inge A.
Li, Mei
de Vries, Tessa
Qin, Tao
Yanagisawa, Takeshi
Sugimoto, Kazutaka
van den Bogaerdt, Antoon
Danser, A. H. Jan
Wermer, Marieke J. H.
van den Maagdenberg, Arn M. J. M.
MaassenVanDenBrink, Antoinette
Ferrari, Michel D.
Ayata, Cenk
author_sort Mulder, Inge A.
collection PubMed
description OBJECTIVE: Calcitonin gene–related peptide (CGRP) pathway inhibitors are emerging treatments for migraine. CGRP‐mediated vasodilation is, however, a critical rescue mechanism in ischemia. We, therefore, investigated whether gepants, small molecule CGRP receptor antagonists, worsen cerebral ischemia. METHODS: Middle cerebral artery was occluded for 12 to 60 minutes in mice. We compared infarct risk and volumes, collateral flow, and neurological deficits after pretreatment with olcegepant (single or 10 daily doses of 0.1–1mg/kg) or rimegepant (single doses of 10–100mg/kg) versus vehicle. We also determined their potency on CGRP‐induced relaxations in mouse and human vessels, in vitro. RESULTS: Olcegepant (1mg/kg, single dose) increased infarct risk after 12‐ to 20‐minute occlusions mimicking transient ischemic attacks (14/19 vs 6/18 with vehicle, relative risk = 2.21, p < 0.022), and doubled infarct volumes (p < 0.001) and worsened neurological deficits (median score = 9 vs 5 with vehicle, p = 0.008) after 60‐minute occlusion. Ten daily doses of 0.1 to 1mg/kg olcegepant yielded similar results. Rimegepant 10mg/kg increased infarct volumes by 60% after 20‐minute ischemia (p = 0.03); 100mg/kg caused 75% mortality after 60‐minute occlusion. In familial hemiplegic migraine type 1 mice, olcegepant 1mg/kg increased infarct size after 30‐minute occlusion (1.6‐fold, p = 0.017). Both gepants consistently diminished collateral flow and reduced reperfusion success. Olcegepant was 10‐fold more potent than rimegepant on CGRP‐induced relaxations in mouse aorta. INTERPRETATION: Gepants worsened ischemic stroke in mice via collateral dysfunction. CGRP pathway blockers might thus aggravate coincidental cerebral ischemic events. The cerebrovascular safety of these agents must therefore be better delineated, especially in patients at increased risk of ischemic events or on prophylactic CGRP inhibition. ANN NEUROL 2020;88:771–784
format Online
Article
Text
id pubmed-7540520
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-75405202020-10-09 Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice Mulder, Inge A. Li, Mei de Vries, Tessa Qin, Tao Yanagisawa, Takeshi Sugimoto, Kazutaka van den Bogaerdt, Antoon Danser, A. H. Jan Wermer, Marieke J. H. van den Maagdenberg, Arn M. J. M. MaassenVanDenBrink, Antoinette Ferrari, Michel D. Ayata, Cenk Ann Neurol Research Articles OBJECTIVE: Calcitonin gene–related peptide (CGRP) pathway inhibitors are emerging treatments for migraine. CGRP‐mediated vasodilation is, however, a critical rescue mechanism in ischemia. We, therefore, investigated whether gepants, small molecule CGRP receptor antagonists, worsen cerebral ischemia. METHODS: Middle cerebral artery was occluded for 12 to 60 minutes in mice. We compared infarct risk and volumes, collateral flow, and neurological deficits after pretreatment with olcegepant (single or 10 daily doses of 0.1–1mg/kg) or rimegepant (single doses of 10–100mg/kg) versus vehicle. We also determined their potency on CGRP‐induced relaxations in mouse and human vessels, in vitro. RESULTS: Olcegepant (1mg/kg, single dose) increased infarct risk after 12‐ to 20‐minute occlusions mimicking transient ischemic attacks (14/19 vs 6/18 with vehicle, relative risk = 2.21, p < 0.022), and doubled infarct volumes (p < 0.001) and worsened neurological deficits (median score = 9 vs 5 with vehicle, p = 0.008) after 60‐minute occlusion. Ten daily doses of 0.1 to 1mg/kg olcegepant yielded similar results. Rimegepant 10mg/kg increased infarct volumes by 60% after 20‐minute ischemia (p = 0.03); 100mg/kg caused 75% mortality after 60‐minute occlusion. In familial hemiplegic migraine type 1 mice, olcegepant 1mg/kg increased infarct size after 30‐minute occlusion (1.6‐fold, p = 0.017). Both gepants consistently diminished collateral flow and reduced reperfusion success. Olcegepant was 10‐fold more potent than rimegepant on CGRP‐induced relaxations in mouse aorta. INTERPRETATION: Gepants worsened ischemic stroke in mice via collateral dysfunction. CGRP pathway blockers might thus aggravate coincidental cerebral ischemic events. The cerebrovascular safety of these agents must therefore be better delineated, especially in patients at increased risk of ischemic events or on prophylactic CGRP inhibition. ANN NEUROL 2020;88:771–784 John Wiley & Sons, Inc. 2020-08-07 2020-10 /pmc/articles/PMC7540520/ /pubmed/32583883 http://dx.doi.org/10.1002/ana.25831 Text en © 2020 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Mulder, Inge A.
Li, Mei
de Vries, Tessa
Qin, Tao
Yanagisawa, Takeshi
Sugimoto, Kazutaka
van den Bogaerdt, Antoon
Danser, A. H. Jan
Wermer, Marieke J. H.
van den Maagdenberg, Arn M. J. M.
MaassenVanDenBrink, Antoinette
Ferrari, Michel D.
Ayata, Cenk
Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice
title Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice
title_full Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice
title_fullStr Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice
title_full_unstemmed Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice
title_short Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice
title_sort anti‐migraine calcitonin gene–related peptide receptor antagonists worsen cerebral ischemic outcome in mice
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540520/
https://www.ncbi.nlm.nih.gov/pubmed/32583883
http://dx.doi.org/10.1002/ana.25831
work_keys_str_mv AT mulderingea antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice
AT limei antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice
AT devriestessa antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice
AT qintao antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice
AT yanagisawatakeshi antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice
AT sugimotokazutaka antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice
AT vandenbogaerdtantoon antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice
AT danserahjan antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice
AT wermermariekejh antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice
AT vandenmaagdenbergarnmjm antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice
AT maassenvandenbrinkantoinette antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice
AT ferrarimicheld antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice
AT ayatacenk antimigrainecalcitoningenerelatedpeptidereceptorantagonistsworsencerebralischemicoutcomeinmice